ライフサイエンスコーパス: vasopressor

1 Physiology and Chronic Health Evaluation II, vasopressor).

2 rformed (100% O2, up to six defibrillations, vasopressors).

3 ndrome, steroids, renal failure and need for vasopressors).

4 risk of hospital mortality based on initial vasopressor.

5 d and 64% received norepinephrine as initial vasopressor.

6 respiratory distress syndrome, and need for vasopressors.

7 ently associated with the mean daily dose of vasopressors.

8 g/dL, and no use of intravenous inotropes or vasopressors.

9 on and 13 of 53 (25%) required initiation of vasopressors.

10 sopressor therapy" being the presence of two vasopressors.

11 continuous hemofiltration, and five required vasopressors.

12 everity of the septic shock and high dose of vasopressors.

13 of intravenous fluid received and receipt of vasopressors.

14 extremely labile cardiovascular responses to vasopressors.

15 ithout an increase in the dose of background vasopressors.

16 cause direct cellular injury insensitive to vasopressors.

17 m bupivacaine-induced cardiac arrest than do vasopressors.

18 y for a temporary pacemaker, or the need for vasopressors.

19 id not respond to high doses of conventional vasopressors.

20 Adult patients with septic shock requiring vasopressors.

21 ry effects of norepinephrine and alternative vasopressors.

22 venous thromboembolism, and those receiving vasopressors.

23 [1.7-3.2]), male (1.3 [1.1-1.7]), received a vasopressor (1.8 [1.3-2.5)]), or had the following clini

24 nvasive mechanical ventilation, 30% required vasopressors, 17% required renal replacement therapy, an

25 ypotension (<90 mm Hg systolic) treated with vasopressors (18%), pulmonary edema (14%), and hyponatre

26 001), intubation (33.3% vs 19.9%; P < .001), vasopressors (23.2% vs 10.9%; P < .001), renal replaceme

27 tics (4.2% vs. 2.6% and 0.8%, p mu .001), or vasopressors (3.9% vs. 1.1% and 0.8%, p mu .001).

28 We enrolled 40 patients (60% requiring vasopressors; 30% mortality).

29 echanical ventilation (65.7% vs. 56.1%), and vasopressors (34.9% vs. 27.8%) were observed, as well as

30 days [range 1-10], p < .001), treatment with vasopressors (35% vs. 5%, p < .001), and treatment with

31 y resuscitation, 2) do not reintubate, 3) no vasopressors, 4) no hemodialysis, 5) do not escalate car

32 77% vs. 48%), to be administered two or more vasopressors (68% vs. 41%), to undergo pulmonary artery

33 e, 62 vs 68), more likely to be treated with vasopressors (69% vs 65%) and had a lower in-hospital mo

34 mechanical ventilation (71.9% vs 90.9%) and vasopressors (70.9% vs 95.0%; p < 0.05), and less likely

35 ion, and shock who were receiving fluids and vasopressors above a threshold dose for 4 hours to recei

36 pha1) and alpha2 (alpha2)-adrenergic agonist vasopressor actions.

37 ntilation, intracranial pressure monitoring, vasopressors, acute neurosurgical intervention, and extr

38 1-3.7) and receive norepinephrine as initial vasopressor (adjusted odds ratio quartile 4 vs quartile

39 the after group were less likely to require vasopressor administration at the time of transfer to th

40 w assesses the maternal and fetal effects of vasopressor administration during spinal anaesthesia for

41 , p < 0.01), and were less likely to require vasopressors after initial fluid resuscitation (68.5% vs

42 n infusion added to at least one concomitant vasopressor agent between January 2014 and December 2015

43 alternative to restore the effectiveness of vasopressor agents during late sepsis.

44 ents who have responded poorly to fluids and vasopressor agents, particularly in the setting of sepsi

45 ith each other were: pulmonary hypertension, vasopressor agents, therapeutics, critical illness, inte

46 rolled 50 patients (28 of 50 [56%] requiring vasopressor agents; 15 of 50 [30%] died).

47 Angiotensin II is an endogenous hormone with vasopressor and endocrine activities.

48 Safety outcomes were delirium-free days, vasopressor and physical restraints use, and device remo

49 orkup was negative but severe instability on vasopressors and a family history of intermittent palpit

50 use of physical restraints, and exposure to vasopressors and antiepileptics.

51 cardiac function, and decreases the need for vasopressors and blood transfusions during the neonatal

52 nt for cardiogenic shock includes inotropes, vasopressors and diuretics.

53 g the most appropriate resuscitation fluids, vasopressors and hemodynamic monitoring systems to maxim

54 pothermia required lower cumulative doses of vasopressors and inotropes.

55 cardiogenic shock unresponsive to inotropes/vasopressors and intraaortic balloon pumps (IABPs).

56 herapy, which relied on more frequent use of vasopressors and lesser use of hyperventilation and osmo

57 provide recommendations regarding the use of vasopressors and pulmonary vasodilators in intensive car

58 few human studies have addressed the use of vasopressors and pulmonary vasodilators in these patient

59 tions of days alive and free of ventilation, vasopressors and renal replacement therapy in 28-day and

60 as defined as persistent hypotension despite vasopressors and requiring mechanical support or procedu

61 Because treatment could not be blinded, vasopressors and ventilatory support were weaned by prot

62 ded age, platelet count, and requirement for vasopressors and/or hemodialysis, each measured on day 2

63 ositive pressure ventilation, 8% versus 19%; vasopressors and/or inotropes, 9% versus 16%; vasodilato

64 with positive blood cultures with concurrent vasopressors and/or lactic acidosis increased (P < .001

65 with positive blood cultures with concurrent vasopressors and/or lactic acidosis remained stable (P =

66 first hospital day, norepinephrine as first vasopressor, and avoidance of starch-based colloids) and

67 7%) required critical care, 9 (24%) required vasopressors, and 7 (18%) died.

68 sive to vasopressors" as the presence of two vasopressors, and 70% stated that they required patients

69 l with administration of intravenous fluids, vasopressors, and blood transfusion decreases mortality

70 Hemodialysis, vasopressors, and blood transfusions were the interventi

71 venous fluid administration, oxygen therapy, vasopressors, and diagnostic tests.

72 ative, elective, hospital type, early use of vasopressors, and dialysis, early deep sedation was an i

73 k if they demonstrated hypotension, received vasopressors, and exhibited a lactate greater than 2 mmo

74 here are significant side effects of current vasopressors, and newer agents need to be developed.

75 Days alive and free of ventilation, vasopressors, and renal replacement therapy in septic sh

76 Youth, a requirement for vasopressors, and renal replacement therapy were additio

77 Days alive and free of ventilation, vasopressors, and renal replacement therapy were highly

78 mmol/L alone or combinations of hypotension, vasopressors, and serum lactate level 2 mmol/L or lower.

79 s SpO2, oximeter characteristics, receipt of vasopressors, and skin pigmentation were recorded at the

80 sease, prolonged ventilation, treatment with vasopressors, and treatment with third-line antiepilepti

81 lization) with mechanical ventilation and/or vasopressors, and/or admission to the intensive care uni

82 markers, including positive blood cultures, vasopressors, and/or lactic acid levels.

83 During septic shock, vasopressors are a cornerstone of therapy.

84 Inotropes and vasopressors are widely used to improve hemodynamics acu

85 majority (72%) defined "poorly responsive to vasopressors" as the presence of two vasopressors, and 7

86 ents were progressively less likely to be on vasopressors at the time of first lactate measurement (4

87 One of three recipients was on a vasopressor before transplantation, and 13% were mechani

88 ne patients (64%) were already receiving two vasopressors before hydrocortisone was prescribed.

89 ents (1.9%) in the usual care group received vasopressors (between-group difference, 12.3% [95% CI, 5

90 d hemoglobin solution decreased the need for vasopressors but was associated with a trend to increase

91 Time to vasopressor cessation, normalization of serum lactate, a

92 l failure, requiring mechanical ventilation, vasopressor circulatory support and intermittent hemodia

93 Among patients with cardiac arrest requiring vasopressors, combined vasopressin-epinephrine and methy

94 length of bypass, administration of pre-CPB vasopressors, core temperature on CPB, pre- and post-CPB

95 ospital length of stay, ventilator days, and vasopressor days.

96 al organ failures were cardiovascular (i.e., vasopressor dependence) and respiratory (i.e., oxygenati

97 bacco use, emergent hematoma evacuation, and vasopressor dependence.

98 mproving myocardial performance and reducing vasopressor dependence.

99 controlled phase III trial in patients with vasopressor-dependent distributive shock, administration

100 glucocorticoid pathways consistently reverse vasopressor-dependent hypotension in septic shock but ha

101 is time seems to be limited to patients with vasopressor-dependent septic shock and patients with ear

102 addition of L-carnitine to the treatment of vasopressor-dependent septic shock.

103 systemic inflammatory response syndrome and vasopressor-dependent shock and increased with age.

104 systemic inflammatory response syndrome and vasopressor-dependent shock receiving protocol-based adr

105 Adult patients with NF and vasopressor-dependent shock undergoing surgical debridem

106 dult patients who had septic shock requiring vasopressors despite fluid resuscitation within a maximu

107 of patients with a 50% decrease in baseline vasopressor dose after 48 hours.

108 A 50% vasopressor dose decrease was significantly more common

109 Vasopressor dose requirements were evaluated before, and

110 Number of vasopressor doses before first shock was higher in the B

111 +/- 0.5 mm Hg; p < 0.05), and the number of vasopressor doses was higher with blood pressure care (m

112 o a systolic blood pressure of 100 mm Hg and vasopressor dosing to maintain coronary perfusion pressu

113 1 mm and standard American Heart Association vasopressor dosing.

114 pth targeted to 51 mm and standard guideline vasopressor dosing.

115 Inotropic and vasopressor drugs are routinely used in critically ill p

116 Use of vasopressor drugs to treat hypotension in acute stroke s

117 steroids produced a significant reduction in vasopressor duration and dosage.

118 (77.6%) was the most frequently used initial vasopressor during septic shock.

119 ceived dopamine or norepinephrine as initial vasopressor during the first 2 days of hospitalization.

120 ine was the most frequently used alternative vasopressor during this time (baseline, 36.2% [95% CI, 3

121 rcumstance, exogenous vasopressin has marked vasopressor effects, even at doses that would not affect

122 We report a case of vasopressor extravasation and threatened limb perfusion

123 We report an event of vasopressor extravasation that was potentially limb thre

124 The case of vasopressor extravasation was successfully treated with

125 placebo), but PHP survivors were weaned off vasopressors faster (13.7 +/- 8.2 vs. 26.3 +/- 21.4 hrs;

126 and December 2012 of whom 58,045 received a vasopressor for septic shock during the first 2 days of

127 l shortage of norepinephrine, the first-line vasopressor for septic shock.

128 aling, may represent an alternative class of vasopressors for use in septic shock.

129 Severity of shock was assessed by the vasopressor-free days and by the mean daily dose of vaso

130 independently associated with the number of vasopressor-free days.

131 ated hemoglobin polyoxyethylene had a longer vasopressor-free time (21.3 vs 19.7 d; p = 0.035).

132 tcome variables were the association between vasopressor genotype pathway polymorphisms, plasma vasop

133 hite blood cells, platelets, albumin, use of vasopressors, Glasgow Coma Scale score, Karnofsky Scale,

134 ilirubin, PaO2, bicarbonate, albumin, use of vasopressors, Glasgow Coma Scale score, Karnofsky Scale,

135 There was no interaction between vasopressor group and allocated target temperature group

136 gan Failure Assessment = 4 defining the high vasopressor group and cardiovascular Sequential Organ Fa

137 The high vasopressor group carried a 53% mortality rate when comp

138 ity rate when compared with a 34% in the low vasopressor group, p(log-rank) less than 0.0001, with an

139 ent less than or equal to 3 defining the low vasopressor group.

140 olic pressure was not a useful metric in the vasopressor groups.

141 The combination of vagolytics and vasopressors has caused maternal hypertensive crises wit

142 ictors of mortality included requirement for vasopressors, hemodialysis, platelet count < or = 150 x

143 nd >/=65 yrs; platelet count 0-150 and >150; vasopressors; hemodialysis) in another logistic regressi

144 k, with dopamine suggested as an alternative vasopressor in selected patients with low risk of tachya

145 e is currently recommended as the first-line vasopressor in septic shock; however, early vasopressin

146 dobutamine infusion administered or added to vasopressor in the presence of a) myocardial dysfunction

147 inistration of intravenous fluid boluses and vasopressors in patients with sepsis across different lo

148 ith administration of intravenous fluids and vasopressors increased in-hospital mortality compared wi

149 ated with hospital mortality included use of vasopressors, infection resulting from P. aeruginosa, in

150 Vasopressor infusion (VPI) is used to treat hypotension

151 Age, mobility/activity, perfusion, and vasopressor infusion emerged as important risk factors f

152 ilability of measurements, especially during vasopressor infusion, represents another serious limitat

153 hours, 24 hours, 72 hours, and 7 days after vasopressor infusion.

154 ypotension following fluid resuscitation and vasopressor infusion.

155 ience poor perfusion, or who are receiving a vasopressor infusion.

156 3+/-1401 ml) and were more likely to receive vasopressor infusions (66.6% vs. 57.8%), red-cell transf

157 therapy (EGDT), in which intravenous fluids, vasopressors, inotropes, and blood transfusions were adj

158 nd oxygen and the use of intravenous fluids, vasopressors, inotropes, and blood transfusions.

159 ified time period; administration of fluids, vasopressors, inotropes, and packed red blood cells titr

160 diothoracic surgery, mechanical ventilation, vasopressors, inotropes, and pulmonary vasodilators.

161 n 10 cm H2O, PaO2/FIO2 less than 300, use of vasopressors/inotropes, pancreatitis, hepatic failure/ci

162 Clindamycin and vasopressor intensity were higher among IVIG cases, as w

163 ich reversed the effects of the extravasated vasopressors: intraosseous phentolamine, topical nitrogl

164 Areas where use of dopamine as initial vasopressor is more common represent potential targets f

165 ory shock that does not respond to high-dose vasopressors is associated with high mortality.

166 al feeding, even when patients are receiving vasopressors, is safe and may actually protect the gut b

167 here that subcutaneous infusion of Ang II, a vasopressor known to promote vascular inflammation, into

168 febrile patients with septic shock requiring vasopressors, mechanical ventilation, and sedation were

169 In patients on a vasopressor medication, 47% (70 of 149) of respondents r

170 CMV infection included a new requirement for vasopressor medications (9%; n = 29), intubation for mec

171 luid restriction, phlebotomy, liberal use of vasopressor medications, and avoidance of preemptive tra

172 e initiation of hydrocortisone (> 9 hr after vasopressors, n = 124).

173 y initiation of hydrocortisone (< 9 hr after vasopressors, n = 46) and those with late initiation of

174 istration would be associated with decreased vasopressor need.

175 d with higher mortality (older age; need for vasopressors; neurologic, respiratory, or hepatic dysfun

176 ethyl gallate vs. those of the commonly used vasopressor, norepinephrine, in a bacteremic canine mode

177 th lower hospital survival were the need for vasopressors (odds ratio, 0.65; 95% CI, 0.43-0.98) and t

178 atio, 1.09; 95% CI, 1.1-1.19; p = 0.04), and vasopressors (odds ratio, 1.16; 95% CI, 1.09-1.23; p < 0

179 dds ratio, 2.04; P=0.008), death or need for vasopressors (odds ratio, 2.70; P<0.001), and the compos

180 idelines recommend norepinephrine as initial vasopressor of choice for septic shock, with dopamine su

181 Phenylephrine is the current vasopressor of choice for the prevention of maternal hyp

182 d) give corticosteroid if the patient is on vasopressor or if adrenal insufficiency is suspected; an

183 return-of-circulation period, absence of any vasopressor or inotropic agent (dopamine, epinephrine) u

184 for hospitals with a lower propensity to use vasopressors or fluids during usual resuscitation.

185 tions if cardiogenic shock was refractory to vasopressors or intra-aortic balloon pump counterpulsati

186 , P<0.001), intraoperative administration of vasopressor (OR 3.14, 95% CI 1.65-5.95, P<0.001), preope

187 ansfusion (odds ratio [OR] 2.7-8.8, P<0.05), vasopressors (OR 2.2, P=0.018), and pre-LT albumin less

188 ay 2014 and required mechanical ventilation, vasopressors, or both.

189 ngth of stay, use of mechanical ventilation, vasopressors, or continuous sedation among individuals i

190 died while receiving mechanical ventilation, vasopressors, or dialysis.

191 eterioration (transfer to ICU, initiation of vasopressors, or invasive mechanical ventilation [IMV] i

192 ion (p < 0.0001, p = 0.0002, and p = 0.001), vasopressors (p < 0.0001, p < 0.0001, and p = 0.0004), a

193 nts with septic shock were genotyped for 268 vasopressor pathway tag single-nucleotide polymorphisms.

194 ically controlled by angiotensins, which are vasopressor peptides specifically released by the enzyme

195 tivity and reduced pressor responsiveness to vasopressors persisted.

196 and no improvement in tissue perfusion (1D); vasopressor preference for norepinephrine or dopamine to

197 ional 22 patients were on a single high-dose vasopressor prior to corticosteroid initiation.

198 stated that they required patients to be off vasopressors prior to altering the corticosteroid dose.

199 ll patients on mechanical ventilation and/or vasopressors, randomized to two usual care sedation regi

200 age was a greater determinant of pressor and vasopressor reactivity.

201 of clonidine in the treatment of persistent vasopressor-refractory hypotension in patients with sept

202 ged, sympathetic overstimulation may lead to vasopressor-refractory hypotension.

203 ining interventions (mechanical ventilation, vasopressors, renal replacement therapy) provided in the

204 A vasopressor requirement (4 points), aspartate aminotrans

205 ptic shock can be clinically identified by a vasopressor requirement to maintain a mean arterial pres

206 , clinical classification, outcome, inotrope/vasopressor requirement, clinical assessment of mortalit

207 90 mm Hg after at least 1L IV fluids, 2) new vasopressor requirement, or 3) systolic blood pressure l

208 r association with the primary outcome: age, vasopressor requirement, thrombocytopenia, preexisting k

209 ncluded age, platelet count, requirement for vasopressors, requirement for hemodialysis, and nontraum

210 sing external cooling was safe and decreased vasopressor requirements and early mortality in septic s

211 hibitor patients had lower total concomitant vasopressor requirements at 24 hours compared with non-r

212 tic calibre, low cardiac output states, high vasopressor requirements causing vasospasm of the artery

213 complications, hospital stay, perioperative vasopressor requirements, and postoperative pain scores

214 Total concomitant vasopressor requirements, based on norepinephrine equiva

215 ant improvement in coagulation, reduction in vasopressor requirements, improvement in blood pH and in

216 rpulsation prolongs survival time and lowers vasopressor requirements.

217 cy may be common in adults and children with vasopressor-resistant shock.

218 Patients with POTS have blunted vasopressor response to Ang II and impaired baroreflex f

219 fetal alpha1-adrenergic pressor and femoral vasopressor responses and enhanced the gain of the fetal

220 Pressor and vasopressor responses to all agonists were greater at 0.

221 We investigated interaction between vasopressor selection and mortality in clinical subgroup

222 actice patterns and outcomes associated with vasopressor selection in a large, population-based cohor

223 or blood pressure (BP), fluid resuscitation, vasopressors, serum lactate level, and base deficit to i

224 Further vasopressor should be used with caution when vagolytic t

225 In septic shock, very high doses of vasopressors sometimes have to be used due to vascular d

226 ich patients develop profound sensitivity to vasopressors, such as angiotensin II, and is associated

227 mbrane oxygenation 5.8% vs 0.9%; p = 0.003), vasopressor support (79.4% vs 55.0%; p < 0.001), and ren

228 ity of the superior vena cava), or increased vasopressor support (right ventricular systolic dysfunct

229 mic inflammatory response syndrome requiring vasopressor support and that steroid administration woul

230 ed levels of lactate, and need for increased vasopressor support compared with targeted temperature m

231 al replacement therapy, invasive monitoring, vasopressor support, and investigational therapies for E

232 taneously breathing patients largely without vasopressor support, the maximal inferior vena cava diam

233 ed ICU admission, mechanical ventilation, or vasopressor support.

234 in patients with SRCS refractory to IABP and vasopressor support.

235 -aortic balloon pump (IABP) and/or high-dose vasopressor support.

236 rterial oxygen saturation and treatment with vasopressors targeting mean arterial pressure (>/=65 mm

237 e fluid resuscitation and combined inotropic/vasopressor therapy (1C); stress-dose steroid therapy gi

238 , mechanical ventilation (26%), and inotrope/vasopressor therapy (26%) were common.

239 ntified to be poorly responsive to fluid and vasopressor therapy (2C); recombinant activated protein

240 sponsive to fluid and moderate- to high-dose vasopressor therapy (conditional, low quality of evidenc

241 Hypotension requiring vasopressor therapy and duration of mechanical ventilati

242 Acute episodes are treated with vasopressor therapy and judicious fluid replacement, pos

243 patients if adequate fluid resuscitation and vasopressor therapy are able to restore hemodynamic stab

244 tified hypotension, serum lactate level, and vasopressor therapy as variables to test using cohort st

245 14 to 2.06] days; P = .01) and alive without vasopressor therapy by 7 days (mean: 5.0 vs 4.7 days; me

246 Vasopressor therapy is required in septic shock to maint

247 e clinical criteria of hypotension requiring vasopressor therapy to maintain mean BP 65 mm Hg or grea

248 effectiveness of vasopressin as the initial vasopressor therapy with or without corticosteroids.

249 poorly responsive to fluid resuscitation and vasopressor therapy" being the presence of two vasopress

250 lprednisolone replacement, fluid management, vasopressor therapy, mechanical ventilation strategies,

251 lacement therapy, mechanical ventilation, or vasopressor therapy.

252 r up to 100 hrs, in addition to conventional vasopressor therapy.

253 volume resuscitation and early initiation of vasopressor therapy.

254 up to 150 hours, in addition to conventional vasopressor therapy.

255 poorly responsive to fluid resuscitation and vasopressor therapy." Because the definition of "poorly

256 ysfunction (47% versus 23% received inotrope/vasopressor therapy; P = 0.02).

257 nous pentobarbital, intravenous mannitol and vasopressor titration for maintenance of cerebral perfus

258 ssor-free days and by the mean daily dose of vasopressor to insure a mean arterial pressure of 65-75

259 les (UG); norepinephrine as the first-choice vasopressor to maintain mean arterial pressure >/= 65 mm

260 per minute or the equivalent dose of another vasopressor to receive infusions of either angiotensin I

261 o a systolic blood pressure of 100 mm Hg and vasopressors to a coronary perfusion pressure greater th

262 blood pressure of 100 mm Hg and titration of vasopressors to maintain coronary perfusion pressure gre

263 emonstrated that the patient group requiring vasopressors to maintain mean BP 65 mm Hg or greater and

264 site and presence of severe sepsis requiring vasopressors to receive either recombinant human KGF (pa

265 ents who developed jaundice (group 1) needed vasopressor treatment (P < 0.05), renal replacement ther

266 Significantly more EDA patients needed vasopressor treatment perioperatively (90% vs 74%, P = 0

267 pression, and vascular hyporesponsiveness to vasopressor treatment.

268 e dose but should not be used as the initial vasopressor (UG); dopamine is not recommended except in

269 tio, 1.37; 95% CI, 1.02-1.83; p = 0.035) and vasopressor use (hazard ratio, 1.84; 95% CI, 1.01-3.35;

270 tio, 1.14; 95% CI, 1.04-1.24; p = 0.004) and vasopressor use (odds ratio, 1.09; 95% CI, 1.02-1.17; p

271 tio, 0.979; 95% CI, 0.963-0.996; p = 0.013), vasopressor use (odds ratio, 1.84; 95% CI, 1.11-3.07; p

272 te IMV (OR, 1.17; 95% CI, .87-1.56), or late vasopressor use (OR, 0.94; 95% CI, .68-1.30).

273 ted with increased diastolic dysfunction and vasopressor use and a greater cumulative positive fluid

274 intubation (52.9% vs. 44.5%, p < 0.001), but vasopressor use and duration of mechanical ventilation w

275 ic vascular resistance that leads to reduced vasopressor use and may result in lower oxygen consumpti

276 There were no differences in vasopressor use and self-extubation.

277 m lactate <2.2 mmol/L and discontinuation of vasopressor use).

278 variates (Model for End-Stage Liver Disease, vasopressor use).

279 d Chronic Health Evaluation III, aspiration, vasopressor use, and thrombocytopenia [platelets </= 80,

280 mission day illness severity, PaO2/FIO2, and vasopressor use, increasing cumulative fluid balance (mL

281 lammatory biomarkers, a higher prevalence of vasopressor use, lower serum bicarbonate concentrations,

282 distress syndrome, temperature, heart rate, vasopressor use, Sequential Organ Failure Assessment sco

283 , not operative case length, hypotension, or vasopressor use, was associated with postoperative press

284 ALI was robust to adjustment for sepsis and vasopressor use.

285 tilation, ICU or hospital length of stay, or vasopressor use.

286 o Logistic Organ Dysfunction score, need for vasopressors, use of antihypertensive agents, need for m

287 arker for shock states, and incorporates all vasopressors used in current clinical practice.

288 (as measured by organ dysfunction or greater vasopressor/ventilator use), and received DrotAA later t

289 he United States, use of dopamine as initial vasopressor was associated with increased mortality amon

290 , the most commonly administered alternative vasopressor was phenylephrine.

291 Use of alternative vasopressors was assessed and a multilevel mixed-effects

292 Time of discontinuation of vasopressors was earlier among patients with initiation

293 arterial pressure and need for high doses of vasopressors were associated with increased mortality in

294 All inotropes and vasopressors were discontinued within 12 hours of pacema

295 al of 155 patients with septic shock in whom vasopressors were initiated and hydrocortisone was presc

296 Inotropes and vasopressors were not administered to either group after

297 Skin pigmentation and receipt of vasopressors were not associated with imputation accurac

298 Vasopressors were tapered to maintain the same blood pre

299 ty-six percent of patients were no longer on vasopressors when the first dosing change was made.

300 ensive care and administered antibiotics and vasopressors within 2 days of admission.